Baseline demographic and clinical characteristics.
| Variable | Placebo, n = 330 | Rilonacept 160 mg, n = 985 |
|---|---|---|
| Age, yrs, mean ± SD | 52.4 ± 10.6 | 52.8 ± 11.5 |
| Male sex, n (%) | 297 (90.0) | 857 (87.0) |
| Race or ethnic group, n (%) | ||
| White | 210 (64.6) | 658 (66.8) |
| Black or African American | 70 (21.2) | 202 (20.5) |
| Asian | 47 (14.2) | 115 (11.7) |
| Other | 3 (0.9) | 10 (1.0) |
| Body mass index, kg/m2, mean ± SD | 31.6 ± 6.0 | 32.2 ± 6.9 |
| Duration of gout, yrs, mean ± SD | 10.6 ± 8.4 | 10.7 ± 9.6 |
| Serum urate concentration, mg/dl, mean ± SD | 8.2 ± 2.0 | 8.0 ± 1.9 |
| Presence of tophi, n (%) | 102 (30.9) | 279 (28.3) |
| Number of gout flares/yr, mean ± SD | 6.1 ± 7.2 | 6.0 ± 6.3 |
| ULT status, n (%) | ||
| Initiating ULT | 212 (64.2) | 614 (62.3) |
| Allopurinol | 209 (63.3) | 611 (62.0) |
| Febuxostat | 1 (0.3) | 4 (0.4) |
| Probenecid | 2 (0.6) | 1 (0.1) |
| Continuing ULT | 118 (35.8) | 371 (37.7) |
| Allopurinol | 114 (34.5) | 363 (36.9) |
| Febuxostat | 2 (0.6) | 9 (0.9) |
| Probenecid | 2 (0.6) | 4 (0.4) |
| Comorbid conditions, n (%) | ||
| Hypertension | 174 (52.7) | 521 (52.9) |
| Hypercholesterolemia | 52 (15.8) | 169 (17.2) |
| Coronary artery disease | 10 (3.0) | 18 (1.8) |
| Diabetes mellitus | 40 (12.1) | 133 (13.5) |
| Renal failure and impairment | 12 (3.6) | 19 (1.9) |
| Sleep apnea | 15 (4.5) | 44 (4.5) |
ULT: urate-lowering therapy.